EUVIMEDEUVIMED entdecken
Crossref

Sentinel Lymph Node Mapping in Endometrial Cancer: Our Initial Experience in a Resource Limited Setting

Szilárd Leó Kiss, Mihai Stanca, Dan Mihai Căpîlna, Tudor Emil Căpîlna, Maria Pop-Suciu, Botond Istvan Kiss, Szilárd Leó Kiss, Mihai Emil Căpîlna

Chirurgia · 2025

DOI: 10.21614/chirurgia.3155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chirurgia, 2025. Verfasst von Szilárd Leó Kiss und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Sentinel Lymph Node Biopsy, Sentinel Lymph Node.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nodal status is one of the most important prognostic factors in endometrial cancer (EC), but systematic lymphadenectomy is associated with significant morbidity. Sentinel lymph node (SLN) mapping offers a less invasive alternative. However, data are limited where indocyanine green is unavailable.

Methods

Between November 2019 and March 2025, 29 women with FIGO stage I-III EC were prospectively enrolled in this study. Cervical injection of methylene blue, with or without technetium-99m, was used for SLN mapping. Ultrastaging was performed routinely. In patients with high-risk disease, full pelvic and para-aortic lymphadenectomy was also performed. Detection rates, sensitivity, and negative predictive value (NPV) were calculated.

Results

Overall and bilateral detection rates were 75% and 48%, respectively (methylene blue: 72% / 44%; dual tracer: 100% / 75%). Nodal metastases were identified in 9 of 29 patients (31%). Patient-level sensitivity was 71%, with an NPV of 88%. Application of the side-specific completion algorithm increased sensitivity to 86%. Side-specific sensitivity and NPV reached 100%. Lymphovascular space invasion and 50% myometrial invasion were significantly associated with nodal metastasis (p 0.05). No mapping-related complications were observed.

Conclusions

SLN mapping with methylene blue, with or without technetium, combined with a side-specific completion algorithm, enables reliable nodal staging even without fluorescence imaging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsSentinel Lymph Node BiopsySentinel Lymph NodeHumansFemaleMiddle AgedMethylene BlueNeoplasm StagingProspective StudiesLymphatic MetastasisAgedLymph Node ExcisionPredictive Value of TestsRadiopharmaceuticalsSensitivity and SpecificityAdult

Stichwörter der Autor:innen

endometrialcancerlymphadenectomymethylenebluenodalstagingresourcelimitedsettingsentinellymphnode

Substanzen

Methylene BlueRadiopharmaceuticals

Zitieren

APA

Kiss, S. L., Stanca, M., Căpîlna, D. M., Căpîlna, T. E., Pop-Suciu, M., Kiss, B. I., Kiss, S. L., & Căpîlna, M. E. (2025). Sentinel Lymph Node Mapping in Endometrial Cancer: Our Initial Experience in a Resource Limited Setting. Chirurgia. https://doi.org/10.21614/chirurgia.3155

Vancouver

Kiss SL, Stanca M, Căpîlna DM, Căpîlna TE, Pop-Suciu M, Kiss BI, et al. Sentinel Lymph Node Mapping in Endometrial Cancer: Our Initial Experience in a Resource Limited Setting. Chirurgia. 2025. doi:10.21614/chirurgia.3155

BibTeX
@article{Kiss2025,
  author = {Kiss, Szilárd Leó and Stanca, Mihai and Căpîlna, Dan Mihai and Căpîlna, Tudor Emil and Pop-Suciu, Maria and Kiss, Botond Istvan and Kiss, Szilárd Leó and Căpîlna, Mihai Emil},
  title = {Sentinel Lymph Node Mapping in Endometrial Cancer: Our Initial Experience in a Resource Limited Setting},
  journal = {Chirurgia},
  year = {2025},
  doi = {10.21614/chirurgia.3155}
}
Kostenlos starten →